Chembio to Present at the Craig-Hallum Alpha Select Conference
MEDFORD, N.Y., Sept. 24, 2013 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.
(Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious
diseases, announces that Lawrence A. Siebert, Chief Executive Officer, will
present at the 4^th Annual Craig-Hallum Alpha Select Conference to be held
September 26, 2013 in New York, NY. Mr. Siebert will be presenting at 2:35
p.m. (ET) in the Flatiron Room, on the 18^th floor of the Convene Conference
Center. One-on-one meetings with investors will be held throughout the day to
discuss the Company's strategy for continued growth. Attendance at the
conference is by invitation only.
The Chembio presentation webcast will be available for public access via the
Investor Relations section of the Chembio corporate Website, www.chembio.com
or at http://wsw.com/webcast/ch3/cemi/ where it will be archived for 90 days.
The Craig-Hallum Alpha Select Conference provides investors with the unique
opportunity to gain insight into companies that are currently on the
Craig-Hallum Alpha Select list or display characteristics that are consistent
with the Alpha Select list - an actively researched collection of small,
under-followed public companies that are believed to have the potential to
become much larger.
About Chembio Diagnostics
Chembio Diagnostics, Inc. develops, manufactures, licenses and markets
proprietary rapid diagnostic tests in the growing $10 billion point-of-care
testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests
are marketed in the U.S. by Alere, Inc. (formerly, Inverness Medical
Innovations, Inc.). Chembio markets its HIV STAT-PAK® line of rapid HIV tests
internationally to government and donor-funded programs directly and through
distributors. Chembio has developed a patented point-of-care test platform
technology, the Dual Path Platform (DPP®) technology, which has significant
advantages over lateral-flow technologies. This technology is providing
Chembio with a significant pipeline of business opportunities for the
development and manufacture of new products based on DPP®. Headquartered in
Medford, NY, with approximately 170 employees, Chembio is licensed by the U.S.
Food and Drug Administration (FDA) as well as the U.S. Department of
Agriculture (USDA), and is certified for the global market under the
International Standards Organization (ISO) directive 13.485. For more
information, please visit: www.chembio.com.
Statements contained herein that are not historical facts may be
forward-looking statements within the meaning of the Securities Act of 1933,
as amended. Forward-looking statements include statements regarding the
intent, belief or current expectations of the Company and its management. Such
statements, which are estimates only, reflect management's current views, are
based on certain assumptions, and involve risks and uncertainties. Actual
results, events, or performance may differ materially from the above
forward-looking statements due to a number of important factors, and will be
dependent upon a variety of factors, including, but not limited to Chembio's
ability to obtain additional financing and to obtain regulatory approvals in a
timely manner, as well as the demand for Chembio's products. Chembio
undertakes no obligation to publicly update these forward-looking statements
to reflect events or circumstances that occur after the date hereof or to
reflect any change in Chembio's expectations with regard to these
forward-looking statements or the occurrence of unanticipated events. Factors
that may impact Chembio's success are more fully disclosed in Chembio's most
recent public filings with the U.S. Securities and Exchange Commission.
CONTACT: Chembio Diagnostics
631-924-1135, ext. 125
Vida Strategic Partners (investor relations)
Stephanie C. Diaz
Press spacebar to pause and continue. Press esc to stop.